Elan has signed an agreement for US firm Abbott Laboratories to use its NanoCrystal Technology.
Abbott will use the technology to develop a single fixed-dose combination of its Tricor medicine and AstraZeneca's Crestor to treat patients with high cholesterol levels.
Elan will receive performance-related payments, based on certain development goals and eventual sales in the United States.
